REFERENCES
- O'Brien KL, Wolfson LI, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374 (9693): 893–902.
- van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374 (9700): 1543–1556.
- Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 2008; 6 (5): 619–635.
- Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bac-terial pneumonia. Int J Antimicrob Agents 2010; 36 (3): 197–204.
- Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15 Suppl 3: 7–11.
- European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European An-timicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2010.
- Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiol 2009; 4: 13–24.
- Prats G, Rossi V, Salvatori E, Mirelis B. Prulifloxacin: a new antibac-terial fluoroquinolone. Expert Rev Anti Infect Ther 2006; 4 (1): 27–41.
- Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221–2236.
- Antimicrobial susceptibility testing EUCAST disk diffusion method. Version 1.0, December 18, 2009. Available at http://www.eucast.org/eu-cast_disk_diffusion_test/disk_diffusion_methodology/.